NCT00904839 - BIBF 1120 Versus Bevacizumab in Metastatic Colorectal Cancer | Biotech Hunter

Enrollment

128

Participants

Timeline

Start Date

May 31, 2009

Primary Completion Date

January 31, 2012

Study Completion Date

January 31, 2012

Conditions

Colorectal Neoplasms

Interventions

DRUG

BIBF 1120

BIBF 1120 100 and 150 mg capsules

DRUG

BIBF 1120

BIBF 1120 100 and 150 mg capsules

DRUG

mFolfox

standard i.v chemotherapy

DRUG

Bevacizumab

100 mg/Kg solution , IV infusion

DRUG

mFolfox 6

IV standard chemotherapy

DRUG

bevacizumab

100 mg/4 ml solution

Trial Locations (47)

Unknown

1199.51.32002 Boehringer Ingelheim Investigational Site, Bonheiden

1199.51.32005 Boehringer Ingelheim Investigational Site, Brussels

1199.51.32006 Boehringer Ingelheim Investigational Site, Brussels

1199.51.32001 Boehringer Ingelheim Investigational Site, Leuven

1199.51.3306A Boehringer Ingelheim Investigational Site, Nice

1199.51.3306B Boehringer Ingelheim Investigational Site, Nice

1199.51.3306C Boehringer Ingelheim Investigational Site, Nice

1199.51.3306D Boehringer Ingelheim Investigational Site, Nice

1199.51.3301A Boehringer Ingelheim Investigational Site, Paris

1199.51.3301B Boehringer Ingelheim Investigational Site, Paris

1199.51.3301C Boehringer Ingelheim Investigational Site, Paris

1199.51.3301D Boehringer Ingelheim Investigational Site, Paris

1199.51.3307A Boehringer Ingelheim Investigational Site, Reims

1199.51.3307B Boehringer Ingelheim Investigational Site, Reims

1199.51.3307C Boehringer Ingelheim Investigational Site, Reims

1199.51.3308A Boehringer Ingelheim Investigational Site, Saint-Herblain

1199.51.3308B Boehringer Ingelheim Investigational Site, Saint-Herblain

1199.51.3308C Boehringer Ingelheim Investigational Site, Saint-Herblain

1199.51.3308D Boehringer Ingelheim Investigational Site, Saint-Herblain

1199.51.3308E Boehringer Ingelheim Investigational Site, Saint-Herblain

1199.51.3305A Boehringer Ingelheim Investigational Site, Toulouse

1199.51.3305B Boehringer Ingelheim Investigational Site, Toulouse

1199.51.3305C Boehringer Ingelheim Investigational Site, Toulouse

1199.51.3305D Boehringer Ingelheim Investigational Site, Toulouse

1199.51.3305E Boehringer Ingelheim Investigational Site, Toulouse

1199.51.3302A Boehringer Ingelheim Investigational Site, Villejuif

1199.51.3302B Boehringer Ingelheim Investigational Site, Villejuif

1199.51.3302C Boehringer Ingelheim Investigational Site, Villejuif

1199.51.3302D Boehringer Ingelheim Investigational Site, Villejuif

1199.51.3302E Boehringer Ingelheim Investigational Site, Villejuif

1199.51.49001 Boehringer Ingelheim Investigational Site, Celle

1199.51.49002 Boehringer Ingelheim Investigational Site, Dresden

1199.51.49003 Boehringer Ingelheim Investigational Site, Freiburg/Breisgau

1199.51.49004 Boehringer Ingelheim Investigational Site, Halle

1199.51.49006 Boehringer Ingelheim Investigational Site, Mainz

1199.51.49008 Boehringer Ingelheim Investigational Site, Schwäbisch Hall

1199.51.39002 Boehringer Ingelheim Investigational Site, Ancona

1199.51.39001 Boehringer Ingelheim Investigational Site, Genova

1199.51.39004 Boehringer Ingelheim Investigational Site, Macerata

1199.51.39005 Boehringer Ingelheim Investigational Site, Reggio Emilia

1199.51.39003 Boehringer Ingelheim Investigational Site, Udine

1199.51.34007 Boehringer Ingelheim Investigational Site, A Coruña

1199.51.34006 Boehringer Ingelheim Investigational Site, Alicante

1199.51.34005 Boehringer Ingelheim Investigational Site, Barakaldo

1199.51.34001 Boehringer Ingelheim Investigational Site, Barcelona

1199.51.34003 Boehringer Ingelheim Investigational Site, Madrid

1199.51.34004 Boehringer Ingelheim Investigational Site, Madrid